Amneal Pharmaceuticals (AMRX) Inventory (2017 - 2026)

Amneal Pharmaceuticals' Inventory history runs 10 years deep, the most recent figure standing at $641.6 million for Q1 2026.

• On a quarterly basis, Inventory rose 6.68% year-over-year to $641.6 million in Q1 2026; TTM through Mar 2026 was $641.6 million, a 6.68% increase from a year earlier, with the FY2025 full-year figure at $606.3 million, down 1.0% from the prior year.
• Inventory improved to $641.6 million in Q1 2026 per AMRX's latest filing, from $606.3 million in the prior quarter.
• Across five years, Inventory topped out at $641.6 million in Q1 2026 and bottomed at $512.2 million in Q1 2022.
• The 5-year median for Inventory is $576.5 million (2023), against an average of $575.6 million.
• Across the five-year window, Inventory increased 9.54% in 2023 and dropped 1.0% in 2025, its largest moves.
• Year by year, Inventory stood at $530.7 million in 2022, then grew by 9.54% to $581.4 million in 2023, then rose by 5.34% to $612.5 million in 2024, then dropped by 1.0% to $606.3 million in 2025, then gained by 5.82% to $641.6 million in 2026.
• Per Business Quant, the three latest AMRX Inventory figures stand at $641.6 million (Q1 2026), $606.3 million (Q4 2025), and $614.5 million (Q3 2025).